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Abstract
Background: Considering cell cycle dependent cytotoxicity, intercalation of chemotherapy and epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) may be a treatment option in non-small cell lung cancer
(NSCLC). This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with
gefitinib (G) versus PC alone in a selected, chemotherapy-naïve population of advanced NSCLC patients with a
history of smoking or wild-type EGFR.
Methods: Eligible patients were chemotherapy-naïve advanced NSCLC patients with Eastern Cooperative Oncology
Group performance status of 0—2. Non-smoking patients with adenocarcinoma or patients with activating EGFR
mutation were excluded because they could benefit from gefitinib alone. Eligible patients were randomized to one
of the following treatment arms: PCG, P 175 mg/m2, and C AUC 5 administered intravenously on day 1 intercalated
with G 250 mg orally on days 2 through 15 every 3 weeks for four cycles followed by G 250 mg orally until
progressive disease; or PC, same dosing schedule for four cycles only. The primary endpoint was the objective
response rate (ORR), and the secondary endpoints included progression-free survival (PFS), overall survival (OS), and
toxicity profile.
Results: A total of 90 patients participated in the study. The ORRs were 41.9 % (95 % confidence interval (CI) 27.0–
57.9 %) for the PCG arm and 39.5 % (95 % CI 25.0–55.6 %) for the PC arm (P = 0.826). No differences in PFS (4.1 vs.
4.1 months, P = 0.781) or OS (9.3 vs. 10.5 months, P = 0.827) were observed between the PCG and PC arms. Safety
analyses showed a similar incidence of drug-related grade 3/4 toxicity. Rash and pruritus were more frequent in the
PCG than in the PC arm.
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Conclusions: PCG did not improve ORR, PFS, and OS compared to PC chemotherapy alone for NSCLC in a clinically
selected population excluding non-smoking adenocarcinoma or mutated EGFR.
Trial registration: The study is registered with ClinicalTrials.gov (NCT01196234). Registration date is 08/09/2010.
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Background
Despite significant advances in the treatment of non-
small-cell lung cancer (NSCLC) over the last two decades,
the results of standard chemotherapy for advanced
NSCLC have reached a plateau and new treatment strat-
egies are necessary. The introduction of epidermal growth
factor receptor (EGFR) inhibitors was considered a prom-
ising strategy. EGFR-tyrosine-kinase inhibitors (TKIs),
specifically gefitinib and erlotinib, are currently considered
the standard first-line treatment for patients with activat-
ing EGFR mutations based on the results of several ran-
domized studies [1–6]. However, the benefit of these
agents is confined to patients with EGFR mutation [7, 8].
The mechanism of action of EGFR inhibitors is the in-
hibition of tumor cell proliferation and induction of
apoptosis. The addition of EGFR inhibitors to standard
chemotherapy is an attractive approach to enhance its
efficacy. However, no survival advantage was detected in
trials such as the INTACT I, II, and TRIBUTE studies
[9–11]. One possible explanation for the failure of these
studies is that tumor cells that were driven to G0/G1
phase by EGFR TKIs may not be sensitive to cytotoxic
chemotherapy. Preclinical studies and several phase 1
and 2 studies showed that sequential treatment with
chemotherapy followed by EGFR TKIs led to synergistic
cytotoxicity [12–16].
The present study examined the effect of gefitinib ad-
ministered for 2 weeks after paclitaxel and carboplatin
(PC) chemotherapy by assessing cell-cycle progression
during chemotherapy in patients with NSCLC. Non-
smoking patients with adenocarcinoma and patients
with mutant EGFR, who were expected to benefit from
gefitinib alone, were excluded from the analysis.
Methods
Study design and population
This study was a single-center, prospective, open-label,
randomized phase II study of paclitaxel and carboplatin
with intercalated gefitinib (PCG) or PC alone (PC) for
advanced NSCLC in a selected population of smokers
with wild-type EGFR.
Patients were eligible for this study if they were
18 years or older, had a histological diagnosis of NSCLC
with metastasis (stage IV) or locally advanced (stage
IIIB) disease with malignant pleural effusion according
to the 6th edition of the American Joint Committee on
Cancer staging system. Inclusion criteria were ≥ 1 meas-
urable lesion meeting Response Evaluation Criteria in
Solid Tumors (RECIST version 1.1) guidelines, an East-
ern Cooperative Oncology Group (ECOG) performance
status (PS) of 0–2, at least 1 week since the last radio-
therapy session, and adequate organ function.
Exclusion criteria included tumors harboring EGFR
mutation, prior systemic chemotherapy for NSCLC,
non-smoking patients with adenocarcinoma (except pa-
tients with wild-type EGFR), symptomatic brain metasta-
sis and any unstable medical condition.
This study was approved by the institutional review
board of Asan Medical Center and was performed in ac-
cordance with the Declaration of Helsinki and Good
Clinical Practice guidelines. All patients gave written in-
formed consent before treatment. This study has been
submitted for registration with ClinicalTrials.gov identi-
fier NCT01196234.
Randomization
Eligible patients were randomly assigned in a 1:1 ratio to
receive PCG or PC alone. Randomization was stratified
by gender and histology (adenocarcinoma, others).
Treatment plan
Patients in the PCG arm received paclitaxel 175 mg/m2
and carboplatin AUC 5 intravenously on day 1 with in-
tercalated gefitinib 250 mg orally once daily from day 2
through day 15 every 3 weeks for four cycles followed by
gefitinib 250 mg orally until progressive disease or un-
acceptable toxicity. Patients in the PC arm received pac-
litaxel 175 mg/m2 and carboplatin AUC 5 intravenously
on day 1 every 3 weeks until progressive disease up to
four cycles without following maintenance therapy.
Dose adjustments were based on drug-related toxic-
ities. When dose reduction was necessary, gefitinib was
stopped every third day. If a patient still required dose
reduction, it was stopped every other day. Any patient
who required three dose reductions or developed inter-
stitial lung disease (ILD) was discontinued from the
study drug. Treatment could be delayed for a maximum
of 2 weeks.
Evaluation
Physical examination, ECOG PS evaluation and toxicity
rating according to the Common Terminology Criteria
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for Adverse Events (CTCAE version 3.0) were performed
at baseline, prior to each cycle, and approximately
1 month after the last dose of the study drug. Tumor re-
sponse was assessed by computed tomography (CT)
with RECIST version 1.1 every 6 weeks during chemo-
therapy, and every 12 weeks thereafter until disease
progression.
Statistical considerations
The aim of this randomized phase II study was to as-
sess the benefit of gefitinib intercalation with PC
chemotherapy. The primary endpoint was objective
response rate (ORR); complete response, (CR) or par-
tial response, (PR). When the usual ORR in the PC
chemotherapy arm was 40 % and an absolute increase
of 15 % in the ORR was obtained by intercalation of
gefitinib to standard PC chemotherapy in each arm of
37 patients, the probability of correctly selecting PC
chemotherapy with gefitinib as superior was 0.9. Con-
sidering follow-up loss, 42 patients were planned to
be enrolled in each arm [17].
ORR was analyzed using the χ2 test and data were
expressed with 95 % confidence interval (CI). The sec-
ondary endpoints were progression-free survival (PFS)
and overall survival (OS), which were assessed using the
Kaplan-Meier method with hazard ratio (HR) and 95 %
CI via Cox’s proportional hazard model.
Results
Between April 2010 and December 2011, 90 patients
were enrolled into the study and randomly assigned to
receive PC with gefitinib (N = 44) or PC alone (N = 46).
Finally, 43 patients in the PCG arm and 43 patients in
the PC arm received at least one cycle of treatment
(Fig. 1). Baseline characteristics were well balanced
across the treatment arms (Table 1). Median age was
60 (range, 44–72) years in the PCG arm and 59
(range, 37–70) years in the PC arm. Approximately
10 % of patients were non-smokers and 63 % had
adenocarcinoma. Patients with stage IV cancer com-
prised about 80 % of each group equally.
Primary efficacy measures
No significant difference in ORR was observed between
the two arms (P = 0.826), with an ORR of 41.9 % (95 %
CI: 27.0–57.9 %) for the PCG arm and 39.5 % (95 % CI:
25.0–55.6 %) for the PC arm (Table 2). No difference in
disease control rate (DCR) was observed between the
two arms, with DCR values of 74.4 % (95 % CI: 58.8–
86.5 %) and 65.1 % (95 % CI: 49.1–79.0 %), respectively
(P = 0.348) (Table 2).
Fig. 1 Trial profile
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Secondary efficacy measures
During a median follow-up of 21.7 months, there were
83 patients with PFS events (disease progression or
death from any cause). No statistically significant differ-
ence in PFS was found between the two arms (HR = 0.94
[95 % CI: 0.61–1.45], P = 0.781). Median PFS was 4.1
(95 % CI: 3.9–4.3) months in the PCG arm and 4.1
(95 % CI: 3.9–4.3) months in the PC arm (Fig. 2).
A total of 66 patients had an OS event (death). No
statistically significant difference in OS was observed
between the groups (HR = 0.95 [95 % CI: 0.58–1.54],
P = 0.827). Median OS was 9.3 (95 % CI: 7.0–11.6)
months in the PCG arm and 10.5 (95 % CI: 8.3–12.7)
months in the PC arm (Fig. 3).
Exploratory analyses
Exploratory subgroup analyses are shown in Fig. 4. The
negative result for the comparison between the PCG
arm and the PC arm was generally consistent through-
out all clinical subsets, although the small number of pa-
tients in several subsets resulted in large CIs and made
the results difficult to interpret.
Table 1 Baseline characteristics of patients (intention to treat population)
Parameter Chemotherapy-gefitinib (PCG) (N = 44) (%) Chemotherapy (PC) (N = 46) (%) Total (N = 90) (%) P-value
Age (years)
Median (range) 60.0 (44–72) 59.0 (37–70) 59.5 (37–72) 0.678
Gender
Male 35 (79.5) 42 (91.3) 77 (85.6)
Female 9 (20.5) 4 (8.7) 13 (14.4) 0.113
Smoking status
Smoker 37 (84.1) 44 (95.7) 81 (90.0)
Non-smoker 7 (15.9) 2 (4.3) 9 (10.0) 0.087
ECOG status
ECOG 0 0 0 0
ECOG 1 44 (100) 46 (100) 90 (100) –
Histological subtype
Adenocarcinoma 24 (54.5) 31 (67.4) 55 (61.1)
Non-adenocarcinoma 20 (45.5) 15 (32.6) 35 (38.9) 0.211
EGFR mutation
Wild-type 6 (13.6) 3 (6.5) 9 (10.0)
Unknown 38 (86.4) 43 (93.5) 81 (90.0) 0.157
Stage of disease
Stage IIIB 8 (18.2) 10 (21.7) 18 (20.0)
Stage IV 36 (81.8) 36 (78.3) 72 (80.0) 0.673
Table 2 Best overall response according to RECIST
Parameter PCG arm (%) (N = 43) PC arm (%) (N = 43) Odds ratio (95 % CI) P-value
Objective response 18 (41.9) 17 (39.5) 0.91 0.826
95 % CI (27.0–57.9) (25.0–55.6) (0.38–2.13)
Disease control 32 (74.4) 28 (65.1) 0.64 0.348
95 % CI (58.8–86.5) (49.1–79.0) (0.25–1.61)
Complete response 0 (0) 0 (0)
Partial response 18 (41.9) 17 (39.5)
Stable disease 14 (32.6) 11 (25.6)
Progressive disease 10 (23.3) 13 (30.2)
Missing 1 (2.3) 2 (4.7)
N number; CI confidence interval
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Safety
Of the 90 patients, 86 received at least one dose of treat-
ment and were included in the safety analyses. The me-
dian number of cycles received in both arms was 4.0.
The two arms showed a similar incidence of drug-
related toxicity. Most AEs were clinically manageable.
The most commonly reported AEs of any grade were
anemia, neutropenia, rash, pruritus, myalgia, neur-
opathy, anorexia, and cough (Table 3). Skin rash and
pruritus were more common in the PCG arm (63 and
37 %) than in the PC arm (5 and 9 %), although no grade
3 rash or pruritus was observed in the PCG arm
(Table 3). Frequency of diarrhea was similar in both
treatment groups (Table 3). Twenty-two patients had at
least one serious adverse event with CTCAE grade 3/4
[10 in the PCG arm (23.3 %) and 12 in the PC arm
(27.9 %)] (Table 3). Three patients died during the study
period, two in the PCG arm (both from infection) and
one in the PC arm (from pulmonary thromboembolism).
Discussion
This randomized phase II study was designed to evaluate
the effect of intercalation therapy with gefitinib and pacli-
taxel/carboplatin chemotherapy as first-line treatment in a
clinically selected population, excluding non-smoking pa-
tients with adenocarcinoma or patients with wild-type
EGFR. Our study demonstrated that gefitinib intercalation
did not improve the efficacy of paclitaxel/carboplatin
chemotherapy in relation to ORR, PFS, and OS. Toxicity
profiles were generally clinically tolerable. Combination
treatment resulted in more frequent skin toxicity.
Earlier studies that assessed the combination of
chemotherapy and EGFR TKIs failed to show a survival
advantage. In two randomized studies, the addition of
daily gefitinib or erlotinib to standard chemotherapy did
not improve OS, time to progression or ORR compared
with chemotherapy alone [9–11].
Two possible combination approaches have been pro-
posed to solve this problem: a pure sequential strategy,
in which chemotherapy is followed by maintenance
EGFR TKI treatment [18, 19], and an intercalated admin-
istration strategy based on cell cycle-dependent cytotox-
icity, which was supported by the results of preclinical and
preliminary clinical studies [12–16].
One preclinical study assessed the effects of sequential
administration of pemetrexed and erlotinib, and showed
cytotoxic synergism in both mutant and wild-type EGFR
cell lines [12]. In another preclinical study, the
sequence-dependent synergism between paclitaxel and
gefitinib was demonstrated in human lung cancer cell
lines with both wild-type and mutant EGFR genes [13].
Several later phase I/II clinical studies showed that an
intercalated regimen of chemotherapy and EGFR TKI is
safe and effective [14–16, 20].
Recently, two clinical studies reported that the interca-
lated regimen offered superior efficacy compared to
chemotherapy or EGFR TKIs alone [21, 22]. In the First-
line Asian Sequential Tarceva and Chemotherapy Trial
(FASTACT)-2, intercalated therapy with gemcitabine
plus platinum and erlotinib improved OS and PFS
Fig. 3 Kaplan-Meier graph of overall survival by treatment group
(ITT population)
Fig. 4 Forest plots by clinical subgroups. yrs, years;
adeno, adenocarcinoma
Fig. 2 Kaplan-Meier graph of progression-free survival by treatment
group (ITT population)
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compared to chemotherapy alone for unselected patients
with advanced stage NSCLC as first-line setting. In sub-
set analyses, patients with wild-type EGFR did not bene-
fit from this intercalated regimen. [21] In a three-arm
phase II study, pemetrexed-erlotinib improved PFS com-
pared to either drug alone in a clinically selected popula-
tion of never-smoking patients with non-squamous
NSCLC as second-line therapy [22].
Because the combination of chemotherapy and EGFR
TKIs showed cytotoxic synergism against wild-type
EGFR NSCLC cell lines in a preclinical study [12, 13]
and this combination was suggested as a new treatment
option for patients with unknown EGFR status in a pre-
vious clinical study [21], we hypothesized that the inter-
calated strategy could be effective in patients with wild-
type or unknown EGFR status. Despite the results of
preclinical and clinical studies, our study failed to show
the efficacy of intercalated therapy in patients with wild-
type EGFR or in a clinically selected population that ex-
cluded non-smoking patients with adenocarcinoma. Al-
though molecular tests are used routinely in clinical
practice, EGFR status remains unknown in certain pa-
tients. The negative result of the present study was con-
sistent with the results of Matjaz Zwitter et al.’s study,
which showed that intercalated treatment was not of
benefit for EGFR wild-type NSCLC [23].
On the other hand, intercalated treatment might be a
promising approach for patients with NSCLC with EGFR
mutant disease or selected patient with unknown EGFR
mutation status, according to several clinical studies
[21–23]. There were some explanations for the high effi-
cacy of the intercalated therapy, including synergism of
different categories of drugs and preventing repopulation
of the tumor. However, a randomized trial comparing in-
tercalated therapy with sequential treatment is needed to
confirm the real value of intercalated therapy for EGFR
mutated NSCLC.
Conclusions
In conclusion, the results of the present study indicated
that intercalated treatment with chemotherapy and EGFR
TKIs does not improve ORR, PFS, and OS compared to
Table 3 Summary of the most common adverse events
PCG arm (N = 43) (%) PC arm (N = 43) (%) P-value
for all grade AEAll grade Gr 3 Gr 4 Gr 5 All grade Gr 3 Gr 4 Gr 5
Patients with ≥ 1 AE (Gr3/4/5) 10 (23) 12 (28) 0.244
aRash 27 (63) 2 (5) <0.001
aPruritis 13 (37) 4 (9) 0.012
Myalgia 25 (58) 28 (65) 0.506
Neuropathy 21 (49) 25 (58) 0.387
Alopecia 24 (56) 21 (49) 0.517
Anorexia 15 (35) 18 (42) 0.506
Cough 16 (37) 11 (26) 0.245
Nausea 13 (30) 8 (19) 0.209
Fatigue 10 (23) 10 (23) 1.000
Dyspepsia 6 (14) 7 (16) 0.763
Constipation 6 (14) 6 (14) 1.000
Diarrhea 5 (12) 5 (12) 1 (2) 1.000
Chest pain 5 (12) 5 (12) 1.000
General weakness 5 (12) 1 (2) 5 (12) 1.000
Infection 6 (14) 4 (9) 2 (5) 3 (7) 3 (7) 0.483
TE event 1 (2) 2 (5) 1 (2) 1 (2) 0.571
Neutropenia 10 (23) 2 (5) 7 (16) 3 (7) 1 (2) 0.660
Febrile neutropenia 0 1 (2) 1.000
Anemia 35 (81) 1 (2) 34 (79) 1 (2) 0.787
Thrombocytopenia 9 (21) 8 (19) 1 (2) 0.787
Leucopenia 6 (14) 2 (5) 6 (14) 1 (2) 1.000
Increased LFT 15 (35) 1 (2) 11 (26) 0.348
AE adverse event; Gr grade; N number, LFT liver function test
asignificant difference between two groups
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chemotherapy alone in patients in a clinically selected
population excluding patients with non-smoking adeno-
carcinoma or mutated EGFR.
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